论文部分内容阅读
目的分析来氟米特联合胸腺肽治疗类风湿性关节炎患者的效果。方法选择35例类风湿性关节炎(RA)患者,应用来氟米特和胸腺肽联合治疗24周,治疗前和治疗12周、24周后评价患者的临床指标、实验室指标和治疗效果。结果治疗12周、24周后临床治疗的总有效率分别为88.6%和91.4%;在晨僵时间、关节肿胀数、关节压痛数、休息痛及握力等临床指标与用药前均有显著差异(P<0.01);在RF、ESR、CRP等实验室指标与用药前均有显著差异(P<0.01)。结论来氟米特联合胸腺肽治疗类风湿性关节炎安全有效。
Objective To analyze the effect of leflunomide combined with thymosin on patients with rheumatoid arthritis. Methods Thirty-five patients with rheumatoid arthritis (RA) were selected. The patients were treated with leflunomide and thymosin for 24 weeks. Before treatment, 12 weeks and 24 weeks after treatment, clinical, laboratory parameters and therapeutic effects were evaluated. Results After 12 weeks of treatment, the total effective rate of clinical treatment after 24 weeks was 88.6% and 91.4% respectively. There were significant differences in clinical symptoms such as joint swelling, joint tenderness, rest pain and grip strength before morning sickness P <0.01). There were significant differences in laboratory indexes such as RF, ESR and CRP before treatment (P <0.01). Conclusions Leflunomide combined with thymosin is safe and effective in the treatment of rheumatoid arthritis.